We are thrilled to announce a groundbreaking project that has the potential to revolutionize the treatment landscape for inflammatory diseases. Thanks to the collaboration between our company and the support of CDTI and FEDER funds, we are embarking on the development of a biosimilar for Certolizumab-C1. This biosimilar, produced in the filamentous fungus Myceliophthora thermophila C1, holds promise in offering cost-effective and accessible treatment options to patients in need.
With this project, we are not only advancing biopharmaceutical innovation but also contributing to the improvement of healthcare accessibility and affordability worldwide. Stay tuned as we continue to make strides towards a healthier future for all.
DEVELOPMENT OF THE PRODUCTION PROCESS AND ANALYTICAL CHARACTERISATION OF CERTOLIZUMAB-C1. A BIOSIMILAR FOR THE TREATMENT OF INFLAMMATORY DISEASES PRODUCED IN THE FILAMENTOUS FUNGUS MYCELIOPHTORA THERMOPHILA C1.
Main objective of the project: development and optimisation at pilot scale of the production and purification process of M. thermophila C1 from a biosimilar.
The project is being carried out in Boecillo (Valladolid), has an estimated duration of 20 months (2020-2021), has a budget of €556,295 and has been co-financed with CDTI and FEDER funds.
DESARROLLO DEL PROCESO DE PRODUCCIÓN Y CARACTERIZACIÓN ANALÍTICA DE CERTOLIZUMAB-C1. UN BIOSIMILAR PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS PRODUCIDO EN EL HONGO FILAMENTOSO MYCELIOPHTORA THERMOPHILA C1
Objetivo principal del proyecto: desarrollo y optimización a escala piloto del proceso de producción y purificación de M. thermophila C1 de un biosimilar.
El proyecto se desarrolla en Boecillo (Valladolid), tiene una duración estimada de 20 meses (2020-2021), cuenta con un presupuesto de 556.295€ y ha sido cofinanciado con fondos CDTI y FEDER.
About 53Biologics:
53Biologics is a CDMO with specialized in biologics production, from pDNA to proteins. In order to serve as leaders in biologics development and manufacturing, our mission is to support you whenever you need us, starting in preclinical development up to commercialization.
For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pdelamadrid@53biologics.com
